L'intérêt à découvert pour Tenet Healthcare donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Tenet Healthcare. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Tenet Healthcare (NYSE:THC) Stock, Rapport sur les intérêts à découvert

TENET HEALTHCARE CORP

Tenet Healthcare

Tenet Healthcare is a Dallas-based healthcare services organization. It operates acute and specialty hospitals (47 as of December 2024) and over 500 ambulatory surgery centers and other outpatient facilities across the US, primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.

Tenet Healthcare Corporation Common Stock

Tenet Healthcare Corp

THC BIOMED INTL LTD ORD by THC BioMed Intl Ltd.

THC Biomed International Ltd

TH International Limited - Ordinary shares

TH International Ltd

TOHO CO LTD ADR by TOHO CO LTD.

THUNDER BRDG CAP PARTNERS IV INC CL A

THUNDER BRDG CAP PARTNERS IV INC UNIT 1 CL A & 1/5 WT EXP

THUNDER BRDG CAP PARTNERS IV INC WT EXP

THC THERAPEUTICS INC by THC Therapeutics, Inc.

THC Therapeutics Inc

Spinnaker ETF Series Cannabis ETF

Tenet Healthcare's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) short percent of float has risen 47.37% since its last report. The company recently reported that it has 4.13 million shares sold short, which is 5.88% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.31 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Tenet Healthcare Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751569226_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Tenet Healthcare has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Tenet Healthcare's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Tenet Healthcare's peer group average for short interest as a percentage of float is 5.10%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

What Does the Market Think About Tenet Healthcare?

<a href="https://www.wsj.com/livecoverage/stock-market-today-trump-tariffs-trade-war-06-09-2025/card/hospital-stocks-fall-after-new-trump-directive-on-medicaid-vAl1E69iscGQaix3k0tK" title="https://www.wsj.com/livecoverage/stock-market-today-trump-tariffs-trade-war-06-09-2025/card/hospital-stocks-fall-after-new-trump-directive-on-medicaid-vAl1E69iscGQaix3k0tK">https://www.wsj.com/livecoverage/stock-market-today-trump-tariffs-trade-war-06-09-2025/card/hospital-stocks-fall-after-new-trump-directive-on-medicaid-vAl1E69iscGQaix3k0tK</a>

News

'Hospital Stocks Fall After New Trump Directive on Medicaid' - WSJ

Watching Tenet Healthcare Shares, Fuzzy Panda Issues Report On Stock

U.S. stock futures were lower this morning, with the Dow futures falling around 0.2% points on Wednesday.
Shares of GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) fell sharply in today's pre-market trading as the company posted results <a href="https://www.benzinga.com/quote/GME/earnings">for its first quarter.</a>
GameStop reported first-quarter revenue of $732.4 million, missing analyst estimates of $754.24 million. The company reported first-quarter adjusted earnings of 17 cents per share, beating analyst estimates of four cents per share, according to Benzinga Pro.
GameStop shares dipped 4.9% to $28.68 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>American Superconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMSC#NASDAQ">AMSC</a>) shares dipped 14.3% to $29.54 in pre-market trading after the company announced a proposed public offering of common stock.</li>
<li>GlycoMimetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) fell 13.4% to $0.1475 in pre-market trading.</li>
<li>GitLab Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLB#NASDAQ">GTLB</a>) fell 12.4% to $42.50 in pre-market trading after the company reported first-quarter financial results and issued second-quarter sales guidance with its midpoint below estimates.</li>
<li>Arrive AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAI#NASDAQ">ARAI</a>) shares dipped 9% to $9.33 in pre-market trading. Arrive AI shares jumped over 62% on Tuesday after the company announced it obtained another patent for its AI-powered smart mailbox platform designed for autonomous and conventional package delivery.</li>
<li>Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) declined 7.9% to $8.16 in pre-market trading.</li>
<li>Twin Hospitality Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWNP#NASDAQ">TWNP</a>) dipped 7.8% to $5.93 in pre-market trading.</li>
<li>Cleveland-Cliffs Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) declined 7.4% to $7.44 in pre-market trading. Shares of steel companies moved lower following reports the U.S. and Mexico are nearing a deal that would remove the Trump Administration's tariffs on steel imports.</li>
<li>Tenet Healthcare Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) fell 7% to $145.50 in pre-market trading after declining more than 5% on Tuesday.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45858699/top-2-tech-and-telecom-stocks-you-may-want-to-dump-in-q2">Top 2 Tech And Telecom Stocks You May Want To Dump In Q2</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

Movers

AMSC

ARAI

GLYC

GTLB

TWNP

GameStop Posts Weak Revenue, Joins American Superconductor, GitLab And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

WIIM

WELL

Shares of medical insurance and medical provider companies are trading lower after President Trump, on June 6, told the Department of Health and Human Services to eliminate waste, fraud and abuse in Medicaid.

Morgan Stanley analyst Craig Hettenbach maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Overweight and raises the price target from $175 to $210.

Price Target

Analyst Ratings

Morgan Stanley Maintains Overweight on Tenet Healthcare, Raises Price Target to $210

Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) has outperformed the market over the past 15 years by 3.39% on an annualized basis producing an average annual return of 15.32%. Currently, Tenet Healthcare has a market capitalization of $15.98 billion. 
Buying $100 In THC: If an investor had bought $100 of THC stock 15 years ago, it would be worth $853.37 today based on a price of $172.01 for THC at the time of writing.
<h3>Tenet Healthcare's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749133828_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today

In the last three months, 12 analysts have published ratings on Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>), offering a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Tenet Healthcare, revealing an average target of $180.5, a high estimate of $230.00, and a low estimate of $137.00. Surpassing the previous average price target of $167.40, the current average has increased by 7.83%.
<img src="https://www.benzinga.com/files/images/story/2025/1748894416_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of Tenet Healthcare's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$171.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$195.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Kevin Fischbeck</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$180.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Jamie Perse</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$154.00</td>
<td>$134.00</td>
</tr>
<tr>
<td>Craig Hettenbach</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$175.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$171.00</td>
<td>$161.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$189.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>A.J. Rice</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$230.00</td>
<td>$217.00</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$137.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Jason Cassorla</td>
<td>Guggenheim</td>
<td>Announces</td>
<td>Buy</td>
<td>$165.00</td>
<td>-</td>
</tr>
<tr>
<td>Craig Hettenbach</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Overweight</td>
<td>$165.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Tenet Healthcare. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Tenet Healthcare compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Tenet Healthcare's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Tenet Healthcare's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/THC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Tenet Healthcare analyst ratings.</a>
<h2>Discovering Tenet Healthcare: A Closer Look</h2>
Tenet Healthcare is a Dallas-based healthcare services organization. It operates acute and specialty hospitals (47 as of December 2024) and over 500 ambulatory surgery centers and other outpatient facilities across the US, primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.
<h3>Tenet Healthcare: A Financial Overview</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Negative Revenue Trend: Examining Tenet Healthcare's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -2.7% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Tenet Healthcare's net margin excels beyond industry benchmarks, reaching 7.77%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Tenet Healthcare's ROE excels beyond industry benchmarks, reaching 9.72%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Tenet Healthcare's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.4% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Tenet Healthcare's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 3.15.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

12 Analysts Assess Tenet Healthcare: What You Need To Know

Barclays analyst Andrew Mok maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Overweight and raises the price target from $171 to $215.

Barclays Maintains Overweight on Tenet Healthcare, Raises Price Target to $215

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>DA Davidson analyst Tom White upgraded eXp World Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPI#NASDAQ">EXPI</a>) from Neutral to Buy and announced a $10.75 price target. eXp World shares closed at $7.67 on Wednesday. <a href="https://www.benzinga.com/quote/expi/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Stephen Baxter upgraded Tenet Healthcare Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) from Equal-Weight to Overweight and raised the price target from $150 to $195. Tenet Healthcare shares closed at $164.67 on Wednesday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Stephen Baxter upgraded HCA Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) from Underweight to Equal-Weight and raised the price target from $320 to $385. HCA Healthcare shares closed at $378.44 on Wednesday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying EXPI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="588" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29084912/image-389-1024x588.png" alt="" class="wp-image-931545" style="width:608px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29084912/image-389-1024x588.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29084912/image-389-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29084912/image-389-768x441.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29084912/image-389.png 1101w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/markets/25/05/45641430/jim-cramer-says-this-quantum-computing-stock-is-so-high-and-too-speculative"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/05/45641430/jim-cramer-says-this-quantum-computing-stock-is-so-high-and-too-speculative">Jim Cramer Says This Quantum Computing Stock Is &#8216;So High&#8217; And &#8216;Too Speculative&#8217;</a> </li>
</ul>
Photo via Shutterstock

Upgrades

EXPI

This Tenet Healthcare Analyst Turns Bullish; Here Are Top 3 Upgrades For Thursday

Wells Fargo analyst Stephen Baxter upgrades Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) from Equal-Weight to Overweight and raises the price target from $150 to $195.

Wells Fargo Upgrades Tenet Healthcare to Overweight, Raises Price Target to $195

During the last three months, 10 analysts shared their evaluations of Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>), revealing diverse outlooks from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $175.6, a high estimate of $230.00, and a low estimate of $137.00. This current average reflects an increase of 3.83% from the previous average price target of $169.12. 
<img src="https://www.benzinga.com/files/images/story/2025/1747256471_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Tenet Healthcare. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kevin Fischbeck</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$180.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Jamie Perse</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$154.00</td>
<td>$134.00</td>
</tr>
<tr>
<td>Craig Hettenbach</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$175.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$171.00</td>
<td>$161.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$189.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>A.J. Rice</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$230.00</td>
<td>$217.00</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$137.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Jason Cassorla</td>
<td>Guggenheim</td>
<td>Announces</td>
<td>Buy</td>
<td>$165.00</td>
<td>-</td>
</tr>
<tr>
<td>Craig Hettenbach</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Overweight</td>
<td>$165.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Tenet Healthcare. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Tenet Healthcare compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Tenet Healthcare's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Tenet Healthcare's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/THC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Tenet Healthcare analyst ratings.</a>
<h2>Get to Know Tenet Healthcare Better</h2>
Tenet Healthcare is a Dallas-based healthcare services organization. It operates acute and specialty hospitals (47 as of December 2024) and over 500 ambulatory surgery centers and other outpatient facilities across the US, primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.
<h3>Tenet Healthcare: Delving into Financials</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Tenet Healthcare's revenue growth over a period of 3M has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately -2.7%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Tenet Healthcare's net margin excels beyond industry benchmarks, reaching 7.77%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Tenet Healthcare's ROE stands out, surpassing industry averages. With an impressive ROE of 9.72%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Tenet Healthcare's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.4%, the company showcases efficient use of assets and strong financial health.
Debt Management: Tenet Healthcare's debt-to-equity ratio is below the industry average. With a ratio of 3.15, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Tenet Healthcare: Insights From 10 Analyst Reviews

B of A Securities analyst Kevin Fischbeck maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Buy and raises the price target from $165 to $180.

B of A Securities Maintains Buy on Tenet Healthcare, Raises Price Target to $180

Truist Securities analyst David Macdonald maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Buy and raises the price target from $175 to $190.

Truist Securities Maintains Buy on Tenet Healthcare, Raises Price Target to $190

Goldman Sachs analyst Jamie Perse maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Neutral and raises the price target from $134 to $154.

Goldman Sachs Maintains Neutral on Tenet Healthcare, Raises Price Target to $154

Morgan Stanley analyst Craig Hettenbach maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Overweight and raises the price target from $165 to $175.

Morgan Stanley Maintains Overweight on Tenet Healthcare, Raises Price Target to $175

These large-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Duolingo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>) shares rose 27.39% after the company reported better-than-expected financial results and raised <a href="https://www.benzinga.com//node/45149547" target="_blank" rel="noreferrer noopener">its FY25 sales guidance</a>. Several analysts <a href="https://www.benzinga.com/quote/duol/analyst-ratings" target="_blank" rel="noreferrer noopener">boosted the price forecast</a>.</li>
<li>CoreWeave, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) shares increased 24.15%.</li>
<li>Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) stock escalated 21.24% after the company reported better-than-expected financial results and raised <a href="https://www.benzinga.com//node/45061907" target="_blank" rel="noreferrer noopener">its FY25 adjusted EPS guidance</a>. Many analysts <a href="https://www.benzinga.com/quote/thc/analyst-ratings" target="_blank" rel="noreferrer noopener">boosted the price forecast</a>.</li>
<li>Carrier Global Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>) stock upped 19.10% after it reported better-than-expected first-quarter financial results<a href="https://www.benzinga.com//node/45135625" target="_blank" rel="noreferrer noopener"> and raised its FY25 guidance</a>.</li>
<li>Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) stock upped 18.90%. Akeso, Inc. announced the Chinese Health Authorities, the National Medical Products Administration (NMPA) approved ivonescimab for a second indication based on the results of the Phase 3 <a href="https://www.benzinga.com//node/45046531" target="_blank" rel="noreferrer noopener">trial, HARMONi-2 or AK112-303</a>.</li>
<li>Aurora Innovation, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>) stock upped 18.31% last week after the company announced it launched its commercial self-driving <a href="https://www.benzinga.com//node/45128218" target="_blank" rel="noreferrer noopener">trucking service in Texas</a>.</li>
<li>Arista Networks, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>) shares were up 16.83% after Rosenblatt upgraded the stock from Sell to Neutral and raised its <a href="https://www.benzinga.com/quote/anet/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast from $55 to $85</a>.</li>
<li>Trane Technologies plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TT#NYSE">TT</a>) stock grew 14.83% after the company reported better-than-expected financial results and raised its FY25 GAAP EPS and <a href="https://www.benzinga.com//node/45108290" target="_blank" rel="noreferrer noopener">sales guidance above estimates</a>. Many analysts <a href="https://www.benzinga.com/quote/tt/analyst-ratings" target="_blank" rel="noreferrer noopener">boosted the price forecast</a>.</li>
<li>DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) shares escalated 13.90% f<a href="https://www.benzinga.com//node/45149628" target="_blank" rel="noreferrer noopener">ollowing strong quarterly sales</a>. Many analysts <a href="https://www.benzinga.com/quote/dxcm/analyst-ratings" target="_blank" rel="noreferrer noopener">revised the price forecast</a>.</li>
<li>XPO Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPO#NYSE">XPO</a>) shares increased 13.81%  after the company reported better-than-expected <a href="https://www.benzinga.com//node/45099967" target="_blank" rel="noreferrer noopener">first-quarter EPS results</a>. Many analysts <a href="https://www.benzinga.com/quote/xpo/analyst-ratings" target="_blank" rel="noreferrer noopener">revised the price forecast</a>.</li>
</ol>
Photo by DANIEL CONSTANTE via Shutterstock

Equities

Large Cap

ANET

CARR

CRWV

DUOL

DXCM

EXAS

SMMT

Duolingo, CoreWeave And DexCom Are Among Top 10 Large-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio?

Barclays analyst Andrew Mok maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Overweight and raises the price target from $161 to $171.

Barclays Maintains Overweight on Tenet Healthcare, Raises Price Target to $171

RBC Capital analyst Ben Hendrix maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Outperform and raises the price target from $183 to $189.

RBC Capital Maintains Outperform on Tenet Healthcare, Raises Price Target to $189

UBS analyst A.J. Rice maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Buy and raises the price target from $217 to $230.

Comments

Tenet Healthcare

Intérêt court

Tenet Healthcare (NYSE:THC) Stock, Rapport sur les intérêts à découvert

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL